Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axogen, Inc. - Common Stock (NQ:AXGN)

34.07 +1.12 (+3.40%)
Streaming Delayed Price Updated: 10:31 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axogen, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
From DJS Law Group
Via Business Wire
News headline image
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
FDA PDUFA goal date extended by three months 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports Second Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 17% Growth or $219 Million 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports 2025 First Quarter Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Chief Financial Officer Transition
Lindsey Hartley, CPA, appointed as Chief Financial Officer to succeed Nir Naor 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. To Host Analyst & Investor Day on March 4th
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Craig Swandal, experienced medical device manufacturing executive, joins leadership team 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.